Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · BridgeBio Oncology Therapeutics, Inc. (BBOT)

BridgeBio Oncology Therapeutics: Chief Medical Officer Yong Ben to resign Jan. 8, 2027

Neutral Impact 4 of 5 leadership Written later

BridgeBio Oncology Therapeutics said its Chief Medical and Development Officer, Yong Ben, gave notice of his resignation on October 30, 2026, effective January 8, 2027. The filing states the departure was not due to any disagreement with the company's operations, policies or practices, and it does not name a successor.

Key points

  • Yong Ben gave notice of resignation as Chief Medical and Development Officer on October 30, 2026.
  • Resignation takes effect January 8, 2027.
  • The company states the resignation was not due to any disagreement over operations, policies or practices.

The filing

CompanyBridgeBio Oncology Therapeutics, Inc. (BBOT)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:01 PM ET
Accession number0001193125-26-449722

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.